SynPhagen is developing a novel technology that will target the microbiome in vivo, thus taking advantage of the commensal host-microbiome relationship. We are generating the next generation of therapies that utilize the microbiome in an un-precedent manner. SynPhaGen is applying gene therapy to the microbiome with the intent of delivering therapeutic nucleic acids in vivo at specific locations where the therapy needs to work. SynPhaGens technology consists of a proprietary platform that results in generation of bacteriophage-derived particles. These particles are precisely generated to target specific bacteria at specific locations in vivo, and then deliver therapeutic nucleic acids, which in turn can result in production of therapeutic proteins or modulation of bacteria metabolic pathways. The modular nature of the technology makes it easy to transition from one targeted therapy and bacteria to another, and to regulate expression levels as well as secretion and localization patterns. SynPhaGens technology can be applied to a variety of disease, given the ubiquity of bacteria and their strategic locations in the human body. The technology will allow the development of new therapies for gut, skin and lung disorders, just to name a few, that are safer and less expensive than conventional and current therapies in development. In addition to humans, SynPhaGen technology can be used to develop novel products that support animal care, cosmetics, agriculture and food production, and the environment.
